CN112262993A - 一种复合多肽钙粉及其制备方法和应用 - Google Patents
一种复合多肽钙粉及其制备方法和应用 Download PDFInfo
- Publication number
- CN112262993A CN112262993A CN202011153951.4A CN202011153951A CN112262993A CN 112262993 A CN112262993 A CN 112262993A CN 202011153951 A CN202011153951 A CN 202011153951A CN 112262993 A CN112262993 A CN 112262993A
- Authority
- CN
- China
- Prior art keywords
- parts
- peptide
- powder
- calcium
- calcium powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 185
- 239000011575 calcium Substances 0.000 title claims abstract description 95
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 94
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 239000000843 powder Substances 0.000 title claims abstract description 75
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 74
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 59
- 239000002131 composite material Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000237502 Ostreidae Species 0.000 claims abstract description 29
- 235000020636 oyster Nutrition 0.000 claims abstract description 29
- 241000251511 Holothuroidea Species 0.000 claims abstract description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims abstract description 22
- 229940034055 calcium aspartate Drugs 0.000 claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 15
- 230000037182 bone density Effects 0.000 claims abstract description 15
- 239000005018 casein Substances 0.000 claims abstract description 15
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000021240 caseins Nutrition 0.000 claims abstract description 15
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 14
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 14
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 14
- 230000001965 increasing effect Effects 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- 239000002994 raw material Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000001605 fetal effect Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 5
- 244000105624 Arachis hypogaea Species 0.000 claims description 5
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 5
- 235000018262 Arachis monticola Nutrition 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 235000020232 peanut Nutrition 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 241000287420 Pyrus x nivalis Species 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000000975 bioactive effect Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 description 79
- 230000000694 effects Effects 0.000 description 34
- 210000000988 bone and bone Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 29
- 210000003734 kidney Anatomy 0.000 description 24
- 241000208340 Araliaceae Species 0.000 description 20
- 241000700159 Rattus Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 206010016256 fatigue Diseases 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 16
- 230000037396 body weight Effects 0.000 description 14
- 230000009182 swimming Effects 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000002929 anti-fatigue Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- 229940069978 calcium supplement Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000965254 Apostichopus japonicus Species 0.000 description 3
- 208000008167 Magnesium Deficiency Diseases 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- -1 calcium amino acid Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000004764 magnesium deficiency Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000009140 magnesium supplementation Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000258161 Stichopus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- SSFMKHSRFMRWFB-NVKWYWNSSA-J dicalcium (2S)-2-aminobutanedioate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O SSFMKHSRFMRWFB-NVKWYWNSSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于保健品技术领域,特别涉及一种复合多肽钙粉及其制备方法和应用,包括由以下重量百分比的组分制成:骨胶原蛋白肽20‑30份、大豆肽10‑30份、海参肽3‑15份、牡蛎肽3‑6份、人参肽2‑5份、麦芽糊精15‑25份、果粉5‑15份、天门冬氨酸钙5‑8份及酪蛋白磷酸肽3‑6。本发明的复合多肽钙粉将植物源的生物活性肽与动物性源的生物活性肽结合,不仅能增强机体免疫力,而且能调节机体的免疫系统,有助于缓解体力疲劳和有助于增加骨密度,适用于易感疲劳及骨质疏松患者的辅助治疗。
Description
技术领域
本发明属于保健品技术领域,特别涉及一种复合多肽钙粉及其制备方法和应用。
背景技术
现代社会中,随着社会竞争的加剧,人们面临着生理、心理的多重压力,作息时间严重不规律,疲劳或慢性疲劳综合症如影随形伴随着现代人,如何能有效、安全缓解现代人的疲劳,改善慢性疲劳综合症的状况,除了心理疏导外,服用有助于缓解体力疲劳的功能食品也是一个非常好的选择。
骨质疏松症是老年人的常见病,是骨骼衰老的表现。近年来随着我国步人老龄化社会,骨质疏松症的发病率逐年增加,这对骨质疏松症的防治工作也提出了更高的要求,中医则认为骨质疏松症主要是肾虚所致。《黄帝内经》云:“肾者,主骨生髓”。中国传统医学认为肾为先天之本,主藏精,主骨生髓,骨的生长发育、强弱与肾精盛衰关系密切。《医经精义》日:“肾藏精,精生髓,髓养骨,故骨者,肾之合也,髓者,精之所生,精足则髓足,髓在骨内,髓足则骨强”。由此可见,补肾对于骨质疏松症的重要性。因此在骨质疏松症的治疗上重点强调补肾,填精益髓,强筋壮骨。
钙是在动物体内含量最多的元素之一,不仅是骨骼组织的主要构成物,而且在机体的生长发育过程中,自始至终支持着整个机体结构,在机体各种生理学和生物学的过程中,起着重要的作用,如对血液凝固、神经肌肉的兴奋性、细胞的粘着、神经冲动的传递、细胞膜功能的维持、酶反应的激活以及激素的分泌等, 都有决定性的影响,其实,钙的流失不是骨钙里的钙大量进入血液,然后排出血液, 只有血钙浓度降到很低的时候,才会有少量的骨钙转变为血钙;而对于正常人,血钙浓度低主要发生在不能从食物中及时补充钙的时候,所以要强调食物中钙的流失,而不是强调骨钙的流失;另外,骨胶原既然是羟基磷灰石的黏合剂,只有当骨骼中黏合剂质量越来越差,数量越来越少,不能有效地将所有的羟基磷灰石分子全部、均匀的粘合起来,并按一定的堆积方式和框架结构固定下来,才会发生骨质疏松,骨钙才会进入血液,造成血钙浓度过高,此时才会有钙排出。因此,骨质疏松的实质是合成新的骨胶原的速度跟不上需要,目前市面上补钙剂种类繁多,但多以单纯补充钙剂为主,认为骨质疏松是钙流失造成的,而未考虑到骨胶原的合成,因此补钙效果不佳。
发明内容
针对现有技术存在的不足,本发明的目的是提供了一种复合多肽钙粉及其制备方法和应用,本发明将植物源的生物活性肽与动物性源的生物活性肽结合,不仅能增强机体免疫力,而且能调节机体的免疫系统,有助于缓解体力疲劳和有助于增加骨密度,适用于易感疲劳及骨质疏松患者的辅助治疗。
为解决上述技术问题,本发明采用如下技术方案:
一种复合多肽钙粉,包括以下重量份数的原料:骨胶原蛋白肽20-30份、大豆肽10-30份、海参肽3-15份、牡蛎肽3-6份、人参肽2-5份、麦芽糊精15-25 份、果粉5-15份、天门冬氨酸钙5-8份及酪蛋白磷酸肽3-6份。
优选的,还包括以下重量份数的原料:牦牛骨髓肽12-17份、胎牛骨髓肽 10-15份、羊骨髓肽14-16份。
优选的,还包括以下份数的原料:豌豆肽5-10份、花生肽5-10份、玉米肽 5-10份。
本发明还保护了一种复合多肽钙粉的制备方法,包括以下步骤:
S1,称取以下重量份数的各原料:骨胶原蛋白肽20-30份、大豆肽10-30 份、海参肽3-15份、牡蛎肽3-6份、人参肽2-5份、麦芽糊精15-25份、果粉 5-15份、天门冬氨酸钙5-8份及酪蛋白磷酸肽3-6份,备用;
S2,将S1中各组分与总组分质量的5%-8%的乙醇溶液混匀,造粒;
S3,50-55℃下干燥1.5-2h,过16-18目筛,得复合多肽钙粉。
优选的,所述S1中果粉为苹果粉、草莓粉、蓝莓粉、雪梨粉中的一种或几种。
优选的,所述S1中各组分混合前做预处理:粉碎并过80-100目筛。
优选的,所述S2中乙醇溶液的体积浓度为75%。
优选的,所述S3中干燥后的复合多肽钙粉的含水量≤7%。
本发明还保护了复合多肽钙粉在制备增强机体免疫力、缓解体力疲劳和增加骨密度保健品中的应用。
与现有技术相比,本发明的有益效果:
1、本发明的复合多肽钙粉将植物源的生物活性肽和动物性源的生物活性肽与天门冬氨酸钙结合,通过天门冬氨酸钙作为钙源,通过植物源的生物活性肽和动物性源的生物活性肽做为胶原蛋白,结合了钙源和胶原蛋白形成螯合型氨基酸钙,螯合型氨基酸钙中的钙并不以通常钙盐的离子方式被吸收,而是作为整个分子的一部分(螯合形式)进入肠绒毛细胞,进入细胞后由于pH值的改变或肽酶的作用而进行全部水解、部分水解或不水解,像一般肽那样随细胞内流动液在主动运输条件下从细胞进入血液并运送至全身。生物活性物氨基酸螯合钙易被动物体吸收,可起到补充钙元素及氨基酸的双重作用,同时提高钙的生物利用率,减少生物体内各元素之间的竞争性拮抗作用,是较为理想的钙补充剂。
2、本发明选用天门冬氨酸钙做为钙源,天门冬氨酸钙补钙剂摄入体内后消化吸收比较快,且能较快地到达骨骼部位而沉积,天门冬氨酸钙是由L-天门冬氨酸和碳酸钙或氢氧化钙或氧化钙经过螯合反应而得到的白色粉末,易吸湿、溶解度高、呈中性、化学结构稳定,吸收率可达到90%以上;天门冬氨酸钙中的钙不仅能增强机体免疫力,还能有助于缓解体力疲劳和增加骨密度,特别是对免疫力低下的中老年人有很好的抵抗疲劳和预防骨质疏松症的作用;疗效稳定,食源性原料安全、无任何毒副作用,可长期食用,具有良好应用前景。
3、中医认为骨质疏松症主要是肾虚所致。《黄帝内经》云:“肾者,主骨生髓”。中国传统医学认为肾为先天之本,主藏精,主骨生髓,骨的生长发育、强弱与肾精盛衰关系密切。《医经精义》日:“肾藏精,精生髓,髓养骨,故骨者,肾之合也,髓者,精之所生,精足则髓足,髓在骨内,髓足则骨强”。由此可见,补肾对于骨质疏松症的重要性。因此本发明在骨质疏松症的治疗上重点强调补肾,填精益髓,强筋壮骨。
本发明中通过海参肽、牡蛎肽、人参肽来针对骨质疏松症的治疗,原因是海参肽、牡蛎肽、人参肽都来源于传统的补肾原料海参、牡蛎和人参。
海参,中药材名,为刺参科动物刺参或其他种海参的全体。功能主治为:补肾益精,养血淘燥。治精血亏损,虚弱劳怯,阳痿,梦遗,小便频数,肠燥便艰。①《本草从新》:补肾益精,壮阳疗痿。②《药性考》:降火滋肾,通肠润燥,除劳怯症。③《食物宜忌》:补肾经,益精髓,消痰涎,摄小便,壮阳疗痿,杀疮虫。海参肽是海参的酶水解物,变为小分子肽后,更容易为人体吸收,除了上述作用,现代药理研究还显示,海参肽可以促进小鼠迟发型变态反应,显著提高小鼠ConA诱导的脾淋巴细胞增殖能力、溶血空斑数和血清溶血素水平,及小鼠巨噬细胞对鸡红细胞吞噬率、吞噬指数和碳廓清指数,提示适量海参肽可以促进细胞免疫和体液免疫功能,增强单核巨噬细胞的活性。使用42mg/kg、83mg/kg、 250mg/kg海参肽(含海参多肽>56%,海参多糖>3%,蛋白质>80%)每日0.4mL 灌胃小鼠30d,结果表明,83mg/kg、250mg/kg海参肽可显著提高小鼠单核-巨噬细胞吞噬指数、NK细胞活性,250mg/kg海参肽还可显著提高小鼠半数溶血值和溶血空斑数,表明海参肽对小鼠体液免疫功能、非特异性免疫功能和NK细胞活性均有明显的增强作用。
牡蛎,牡蛎肉含有丰富的钙、磷、铁、锌、镁、锰和硒等成分,钙含量接近牛奶,铁含量为牛奶的20倍;锌的含量尤其丰富,居人类食物之首,100g牡蛎肉中含锌47mg,为海参的76倍,瘦猪肉的30倍,苹果的500倍。目前微量元素缺乏与骨质疏松的关系已引起人们的极大关注,微量元素对维持人体的正常生理活动起着重要作用,骨的正常代谢与多种微量元素密切相关。锌在维持正常的骨代谢中起着重要的作用,锌是碱性磷酸酶、胶原酶的辅基,对于维持和保证该酶的活性非常重要,碱性磷酸酶是完成骨矿化过程中的一个重要酶类,能加速软骨细胞分裂,促进骨细胞的增殖,并增强成骨细胞的活性,加速新骨的钙化, 锌缺乏将降低碱性磷酸酶的活性,使骨活动中的焦磷酸盐水解,从而使骨钙化减少,骨量降低。镁是组成骨的重要成分之,镁在骨的矿质代谢中有关键的调节作用,与钙调激素亦有关系,镁不足可刺激甲状旁腺素(PTH)分泌,促进骨吸收,镁增强靶组织的敏感性以及激活维生D代谢,促进钙吸收;镁缺乏则可改变钙的代谢及钙调激素,补充镁可改善骨密度,轻微的镁缺乏即能损害人体内矿物质平衡, 是骨质疏松的危险因素,骨质疏松症常伴随镁缺乏,治疗骨质疏松不仅需补钙, 应同时补镁。另外,其他的一些微量元素如铁、硒等缺乏与骨质疏松之间也有密切的关系。牡蛎肉中含有丰富的钙、锌、铁、镁、硒等元素,可以补充矿物质的丢失,补充骨代谢过程所需要的微量元素,纠正骨代谢紊乱。牡蛎肽为牡蛎的酶水解物,其有收敛固涩,清热益阴,软坚化痰,敛阴潜阳的作用,能够增强机体免疫力。牡蛎提取物对艾滋病毒感染者和正常人的免疫细胞的影响。发现牡蛎提取物在激活剂白介素2(IL2)存在时,能够促使T细胞大量增殖,以减缓艾滋病患者免疫功能下降的趋势。研究证明,牡蛎提取物对小鼠的免疫功能有正向调节作用,可以阻碍由环磷酰胺所引起的免疫低下反应。研究发现25mg/mL牡蛎多糖能有效增加正常小鼠的脾淋巴细胞转化率、对小鼠DNT、NK细胞活性、PFC、小鼠腹腔巨噬细胞吞噬鸡红细胞能力、荷瘤小鼠脾细胞活性起正向调节,表明牡蛎多糖能增强小鼠细胞免疫、体液免疫功能。
人参肽是指从人参中提取的由10个或10个以下氨基酸组成的小分子低聚肽。研究表面人参多肽具有一定的降血糖作用,可对肾上腺、四氧嘧啶和葡萄糖所引起的高血糖有一定的抑制作用,并能增强肾上腺素对肝糖原的分解;同时人参多肽还可在一定程度上延缓实验小鼠疲劳的产生和加速其疲劳的消除,从而起到抗疲劳的作用,具备作为一种新型抗疲劳制剂的潜力,每天口服0.125~ 1.000g/kg人参多肽的小鼠在抗疲劳模型中表现出显著的抗疲劳活性,同时可以提高小鼠乳酸脱氢酶活性、降低血液乳酸质量浓度、增强小鼠肝糖原的储备,提高小鼠耐力,延缓疲劳。
4、本发明从中医理论出发,结合现代医学研究成果,从使用传统补肾原料 (海参、牡蛎、人参等)入手,不仅能有效改善人体肾虚症状,从而达到缓解人体疲劳的目的;肾主骨生髓,补肾的同时能促进人体骨质疏松状态的改善;另外结合现代医学成果,在直接补充钙源的同时补充胶原蛋白肽和酪蛋白磷酸肽等肽源,能快速起效达到补充钙的作用;使得产品不仅具备缓解体力疲劳的功效,还兼具有补钙从而具有改善骨质疏松的其它作用,一举多得。
具体实施方式
下面对本发明的几个具体实施方式进行详细描述,但应当理解本发明的保护范围并不受具体实施方式的限制。
实施例1
一种复合多肽钙粉包括以下重量份数的原料:骨胶原蛋白肽25份、大豆肽 20份、海参肽10份、牡蛎肽5份、人参肽4份、麦芽糊精20份、果粉10份、天门冬氨酸钙6份及酪蛋白磷酸肽5份,制备方法包括如下步骤:
S1,配料:称取骨胶原蛋白肽25份、大豆肽20份、海参肽10份、牡蛎肽5 份、人参肽4份、麦芽糊精20份、果粉10份、天门冬氨酸钙6份及酪蛋白磷酸肽5份,备用;
菌检:对主要原料和辅料分别进行菌检,控制原辅料的微生物指标在合格范围内;
S2,过筛:检查主要原料和辅料是否有结块现象,粉碎并进行过筛,电动筛目数为80目:
量取6份体积浓度为75%的乙醇溶液,并与S1中各组分混匀,采用双锥混合设备混合均匀,混合时间20min,转速30r/min,然后造粒;
S3,在50℃下干燥2h,过16目筛,使干燥后的复合多肽钙粉的含水量达到 5-6%,得复合多肽钙颗粒,最后包装、检测、入库。
实施例2
一种复合多肽钙粉包括以下重量份数的原料:骨胶原蛋白肽20份、大豆肽 10份、海参肽3份、牡蛎肽3份、人参肽2份、麦芽糊精15份、果粉5份、天门冬氨酸钙5份及酪蛋白磷酸肽3份。制备方法步骤如下:
S1,配料:称取骨胶原蛋白肽20份、大豆肽10份、海参肽3份、牡蛎肽3 份、人参肽2份、麦芽糊精15份、果粉5份、天门冬氨酸钙5份及酪蛋白磷酸肽3份,备用;
菌检:对主要原料和辅料分别进行菌检,控制原辅料的微生物指标在合格范围内;
S2,过筛:检查主要原料和辅料是否有结块现象,粉碎并进行过筛,电动筛目数为90目;
量取8份体积浓度为75%的乙醇溶液,并与S1中各组分混匀,采用双锥混合设备混合均匀,混合时间20min,转速30r/min,然后造粒;
S3,在55℃下干燥1.5h,过17目筛,使干燥后的复合多肽钙粉的含水量达到4-5%,得复合多肽钙颗粒,最后包装、检测、入库。
实施例3
一种复合多肽钙粉包括以下重量份数的原料:骨胶原蛋白肽20份、大豆肽 10份、海参肽3份、牡蛎肽3份、人参肽2份、麦芽糊精15份、果粉5份、天门冬氨酸钙5份及酪蛋白磷酸肽3份。制备方法步骤如下:
S1,配料:称取骨胶原蛋白肽20份、大豆肽10份、海参肽3份、牡蛎肽3 份、人参肽2份、麦芽糊精15份、果粉5份、天门冬氨酸钙5份及酪蛋白磷酸肽3份,备用;
菌检:对主要原料和辅料分别进行菌检,控制原辅料的微生物指标在合格范围内;
S2,过筛:检查主要原料和辅料是否有结块现象,粉碎并进行过筛,电动筛目数为90目:
量取8份体积浓度为75%的乙醇溶液,并与S1中各组分混匀,采用双锥混合设备混合均匀,混合时间20min,转速30r/min,然后造粒;
S3,在55℃下干燥1.5h,过18目筛,使干燥后的复合多肽钙粉的含水量达到4-5%,得复合多肽钙颗粒,最后包装、检测、入库。
实施例4
一种复合多肽钙粉包括以下重量份数的原料:骨胶原蛋白肽25份、大豆肽 20份、海参肽10份、牡蛎肽5份、人参肽4份、麦芽糊精20份、果粉10份、天门冬氨酸钙6份、酪蛋白磷酸肽5份、牦牛骨髓肽12份、胎牛骨髓肽10份及羊骨髓肽14份,制备方法步骤如下:
S1,配料:称取骨胶原蛋白肽25份、大豆肽20份、海参肽10份、牡蛎肽5 份、人参肽4份、麦芽糊精20份、果粉10份、天门冬氨酸钙6份、酪蛋白磷酸肽5份、牦牛骨髓肽15份、胎牛骨髓肽15份及羊骨髓肽15份,备用;
菌检:对主要原料和辅料分别进行菌检,控制原辅料的微生物指标在合格范围内;
S2,过筛:检查主要原料和辅料是否有结块现象,粉碎并进行过筛,电动筛目数为80目:
量取12份体积浓度为75%的乙醇溶液,并与S1中各组分混匀,采用双锥混合设备混合均匀,混合时间20min,转速30r/min,然后造粒;
S3,在50℃下干燥1.5h,过16目筛,使干燥后的复合多肽钙粉的含水量达到5-6%,得复合多肽钙颗粒,最后包装、检测、入库。
实施例5
与实施例4的操作过程相同,不同之处仅在于,将原料中的牦牛骨髓肽12 份替换为牦牛骨髓肽17份、胎牛骨髓肽10份替换为胎牛骨髓肽15份,羊骨髓肽14份替换为羊骨髓肽16份。
实施例6
与实施例4的操作过程相同,不同之处仅在于,将原料替换为骨胶原蛋白肽 25份、大豆肽20份、海参肽10份、牡蛎肽5份、人参肽4份、麦芽糊精20份、果粉10份、天门冬氨酸钙6份、酪蛋白磷酸肽5份、豌豆肽5份、花生肽5份及玉米肽5份。
实施例7
与实施例6的操作过程相同,不同之处仅在于,将原料中的豌豆肽5份替换为豌豆肽10份,花生肽5替换为花生肽10份,玉米肽5份替换为玉米肽10份。
本发明实施例1-实施例7制备得到的复合多肽钙粉均不仅能增强机体免疫力,而且能调节机体的免疫系统,有助于缓解体力疲劳和有助于增加骨密度,适用于易感疲劳及骨质疏松患者的辅助治疗,为了表明本发明的有助于缓解体力疲劳和有助于增加骨密度的保健效果,将实施例1-3制得的复合多肽钙粉、实施例 4及实施例6的缓解体力疲劳和增加骨密度的有益效果进行研究,具体方法如下:
一、小鼠负重游泳实验
(1)实验动物:昆明种小鼠80只,雌雄小鼠各40只,个体质量20-25g。
(2)实验仪器:游泳箱(40cm×55cm×55cm)
(3)实验方法:将128只小鼠随机分为6组,分为实验1-5组及空白对照组,实验1-5组每组24只,空白对照组8只,且每组中雌雄各半,在进行实验研究的过程中向空白对照组给予去离子水,实验1-5组分别给予实施例1-实施例 3、实施例4及实施例6中的产品进行灌胃,并使得每个实验组均分成3个小组,每个小组内8只昆明种小鼠,每组分别按0.03g/kg体重灌服10d、0.3g/kg体重灌服10d、再0.90g/kg体重连续灌胃灌服10d,于末次给予小鼠受试物30min后进行抗疲劳指标测定:
(4)负重游泳试验
取每组8只小鼠末次灌胃30min后,尾根部负荷小鼠体质量5%的铅丝,置于游泳箱中,水深30cm,水温25℃,记录小鼠从游泳开始至死亡的时间。
(5)血乳酸的测定
每组8只小鼠末次灌胃30min后,尾根部负荷小鼠体质量5%的铅丝,置于游泳箱中,水深30cm,水温25℃,游泳10min停止,分别从游泳前、游泳之后0、15、60min的小鼠眼内眦静脉丛取血,于5ml离心管中加入质量分数为1%的NaF溶液0.48ml,准确吸取全血20μl加入试管底部。用试管上清液冲洗微量吸管数次,再加入蛋白沉淀剂1.5ml,振荡混匀,3000r/min离心条件下离心10 min,取上清液测定。
(1)负重游泳试验实验结果
表1复合多肽钙粉对小鼠负重游泳时间的影响
由表1可见,实施例1-实施例3、实施例4及实施例6的小鼠的游泳时间均长于空白对照组的游泳时间,说明在给小鼠灌服本发明的复合多肽钙粉后能够提升小鼠的抗疲劳能力,实施例1的0.03g/kg体重和0.3g/kg体重的复合多肽钙粉可以明显延长小鼠负重时间,差异有显著性(0.03g/kg体重的实施例1的P<0.01, 0.3g/kg体重的实施例1的P<0.05);0.03g/kg体重和0.3g/kg体重的实施例2的复合多肽钙粉可以明显延长小鼠负重时间,差异有显著性(0.03g/kg体重实施例2的 P<0.05,0.3g/kg体重实施例2的P<0.01),说明本发明制备得到的复合多肽钙粉具有明显的抗疲劳效果,且实施例1-实施例3的游泳时间与实施例4及实施例6 的游泳时间相比,低于实施例4及实施例6的游泳时间,说明实施例4及实施例 6的复合多肽钙粉的抗疲劳能力优于实施例1-实施例3的复合多肽钙粉。
(2)血乳酸测定结果
表2复合多肽钙粉对小鼠血乳糖的影响
实验1-5组的中高低三个剂量在游泳后0min和15min与对照组相比,血乳酸含量都分别降低了25%左右(e<0.051),并且在15min时趋于游泳前的乳酸含量,见表2。运动后15min内血乳酸含量分别降低,说明复合多肽钙粉具有促进体力性疲劳消除的积极作用,而且中高低剂量都有类似的作用。且实施例1-实施例3的血乳糖与实施例4及实施例6的血乳糖相比,略高于实施例4及实施例6 的血乳糖,说明实施例4及实施例6的复合多肽钙粉的促进体力性疲劳消除优于实施例1-实施例3的复合多肽钙粉。
二、小鼠骨密度影响实验
按中华人民共和国卫生部颁布的《保健食品检验与评价技术规范》(2003年版)方法操作。对大鼠抗骨质疏松症的作用主要考察大鼠体重;股骨长度、湿重、干重;股骨骨密度和骨硬度;
(1)实验动物:6月龄SD大鼠110只,SPF级,体重80±10g,雌性和雄性各半。
(2)实验仪器:XR-36型双能X线骨密度仪
(3)实验方法:
大鼠适应性喂养3d后,随机分为17组,每组10只,包括低钙对照组、碳酸钙对照组、及实验1-实验5组,实验1-实验5组每组30只大鼠,并在每个实验组中均分10只1组,分为3组,对低钙对照组饲喂Ca含量为0mg/kg体重的饲料,并每日灌胃每100g体重给予1.0mL去离子水;对碳酸钙对照组饲喂 160mg/kg体重的碳酸钙;实验1-5组分别饲喂实施例1-3、实施例4及实施例6 制备得到的复合多肽钙粉,对实验1-实验5组饲喂的每组30个大鼠中的3个小组的分别饲喂5倍、10倍及30倍人体推荐量的受试物组(分别为150mg/kg体重、 300mg/kg体重、900mg/kg体重),给样方法为灌胃。各组大鼠连续饲养3周后进行3d钙代谢实验,测定钙吸收率,继续喂养至13周,实验结束时检测各组大鼠身长,体重变化和股骨密度含量。
股骨密度测定方法:采用XR-36型双能X线骨密度仪测定股骨样品中点及远心端的骨密度;
(4)实验结果:
表3复合多肽钙粉对大鼠身长的影响
从表3可见,碳酸钙对照组饲喂160mg/kg体重和实验1-5组饲喂150mg/kg 体重的大鼠相比,在始长上无明显差异,但是在第4周身长的对比中出现明显的差异,与碳酸钙对照组比较差异有显著性意义(P<0.01),其中实施例2组动物喂养第4周时的身长与相同水平碳酸钙对照组比较身长增长最大。且实施例1-实施例3的大鼠身长与实施例4及实施例6的大鼠身长相比,略低于实施例4及实施例6的大鼠身长,说明实施例4及实施例6的复合多肽钙粉促进大鼠生长优于实施例1-实施例3的复合多肽钙粉。
表4复合多肽钙粉对大鼠股骨骨密度的影响
从表4可见,实验2组动物左侧股骨中点及远端骨密度与低钙对照组和碳酸钙对照组比较增加,经统计学检验,差异有非常显著性意义(P<0.01),表明骨密度结果阳性。且实施例1-实施例3的左侧股骨中点及远端骨密度与实施例4及实施例6的左侧股骨中点及远端骨密度相比,略低于实施例4及实施例6的左侧股骨中点及远端骨密度,说明实施例4及实施例6的复合多肽钙粉促进左侧股骨中点及远端骨密度优于实施例1-实施例3的复合多肽钙粉。
三、有助于增加骨密度的临床文献
根据文献《氨基酸螯合钙用于孕期补钙的临床对比观察》,将口服天门冬氨酸钙制剂和口服葡萄糖酸钙制剂进行临床对比发现,口服天门冬氨酸钙制剂可以明显减少孕妇缺钙的临床症状(肢体麻木、小腿痉挛、腰腿疼痛等),且发生率降低比例较口服葡萄糖酸钙组有极显著差异(P<0.01)。
四、实验结论:实施例1具有显著抗疲劳保健效果,实施例2具有显著提高骨密度效果,实施例3在抗疲劳和提高骨密度上也具有一定保健效果。
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。
Claims (9)
1.一种复合多肽钙粉,其特征在于,包括以下重量份数的原料:骨胶原蛋白肽20-30份、大豆肽10-30份、海参肽3-15份、牡蛎肽3-6份、人参肽2-5份、麦芽糊精15-25份、果粉5-15份、天门冬氨酸钙5-8份及酪蛋白磷酸肽3-6份。
2.根据权利要求1所述的一种复合多肽钙粉,其特征在于,还包括以下重量份数的原料:牦牛骨髓肽12-17份、胎牛骨髓肽10-15份、羊骨髓肽14-16份。
3.根据权利要求1所述的一种复合多肽钙粉,其特征在于,还包括以下重量份数的原料:豌豆肽5-10份、花生肽5-10份、玉米肽5-10份。
4.根据权利要求1所述的一种复合多肽钙粉的制备方法,其特征在于,包括以下步骤:
S1,称取以下重量份数的各原料:骨胶原蛋白肽20-30份、大豆肽10-30份、海参肽3-15份、牡蛎肽3-6份、人参肽2-5份、麦芽糊精15-25份、果粉5-15份、天门冬氨酸钙5-8份及酪蛋白磷酸肽3-6份,备用;
S2,将S1中各组分与总组分质量的5%-8%的乙醇溶液混匀,造粒;
S3,50-55℃下干燥1.5-2h,过16-18目筛,得复合多肽钙颗粒。
5.根据权利要求4所述的复合多肽钙粉的制备方法,其特征在于,所述S1中果粉为苹果粉、草莓粉、蓝莓粉、雪梨粉中的一种或几种。
6.根据权利要求4所述的复合多肽钙粉的制备方法,其特征在于,所述S1中各组分混合前做预处理:粉碎并过80-100目筛。
7.根据权利要求4所述的复合多肽钙粉的制备方法,其特征在于,所述S2中乙醇溶液的体积浓度为75%。
8.根据权利要求4所述的复合多肽钙粉的制备方法,其特征在于,所述S3中干燥后的复合多肽钙粉的含水量≤7%。
9.根据权利要求1所述的一种复合多肽钙粉在制备增强机体免疫力、缓解体力疲劳和增加骨密度保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011153951.4A CN112262993A (zh) | 2020-10-26 | 2020-10-26 | 一种复合多肽钙粉及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011153951.4A CN112262993A (zh) | 2020-10-26 | 2020-10-26 | 一种复合多肽钙粉及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112262993A true CN112262993A (zh) | 2021-01-26 |
Family
ID=74341831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011153951.4A Pending CN112262993A (zh) | 2020-10-26 | 2020-10-26 | 一种复合多肽钙粉及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112262993A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110897029A (zh) * | 2019-11-22 | 2020-03-24 | 上海同济生物制品有限公司 | 一种动植物多肽压片糖果及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110403116A (zh) * | 2018-04-26 | 2019-11-05 | 北京诺贝肽生物工程研究中心(有限合伙) | 一种阿胶肽固体饮料及其制作方法 |
-
2020
- 2020-10-26 CN CN202011153951.4A patent/CN112262993A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110403116A (zh) * | 2018-04-26 | 2019-11-05 | 北京诺贝肽生物工程研究中心(有限合伙) | 一种阿胶肽固体饮料及其制作方法 |
Non-Patent Citations (1)
Title |
---|
刘向阳: "《自制养生豆浆大全》", 31 July 2015, 中医古籍出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110897029A (zh) * | 2019-11-22 | 2020-03-24 | 上海同济生物制品有限公司 | 一种动植物多肽压片糖果及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101248882B (zh) | 一种具有促进骨骼和骨关节健康的营养食品 | |
CN104839718A (zh) | 一种粉剂型全营养配方食品及其生产工艺 | |
CN108703249A (zh) | 一种胶原蛋白产品及其制备方法 | |
CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
CN104982937B (zh) | 一种促进骨质及骨膜修复的组合物及其制备方法 | |
CN103734582A (zh) | 一种适用于中老年人群的牦牛乳蛋白多肽营养粉及其制备方法 | |
CN102488278A (zh) | 一种具有双功能保健作用的复合真菌营养液 | |
CN108095072A (zh) | 供长期卧床及肌肉衰减综合征人群食用短肽特膳食品配方 | |
CN109198647A (zh) | 一种能提高航天员骨质结构的营养制剂 | |
CN113632851A (zh) | 一种多功能儿童生长奶粉及其制备方法 | |
CN111772194A (zh) | 补气安神、益精固肾的食品配方 | |
CN109007649A (zh) | 一种海参牡蛎糖肽钙络合复配物的制备方法及其应用 | |
CN115399449A (zh) | 一种骨营养雪花片的制备方法 | |
CN105942297A (zh) | 一种海参粉及制备方法 | |
CN103656626B (zh) | 一种中老年治骨养骨复方络合钙制剂及其制备方法 | |
CN101279089B (zh) | 阿胶钙组合物及其制备方法 | |
CN112262993A (zh) | 一种复合多肽钙粉及其制备方法和应用 | |
CN1101700C (zh) | 多肽口服液 | |
CN101416734B (zh) | 一种改善骨骼及关节功能的保健品及其制备方法 | |
CN113273655A (zh) | 复合肽蛋白固态饮料 | |
CN115969961B (zh) | 改善骨密度的钙、vd、蛋白肽组合物及其制备方法和应用 | |
CN104939089A (zh) | 具有改善骨密度功能的营养组合物及其制备方法与应用 | |
CN108042786A (zh) | 一种用于增加骨密度的大鲵多肽复合口服饮品 | |
CN106418067A (zh) | 一种补充体力、缓解疲劳的保健饮料 | |
CN106417619A (zh) | 一种促进骨骼生长和提高免疫力的乳钙粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210126 |